Carlumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Carlumab
Monoclonal antibody
Type Whole antibody
Source Human
Target MCP-1
Identifiers
CAS Number 915404-94-3 N
ATC code none
ChemSpider none
Chemical data
Formula C6442H9966N1706O2018S40
Molar mass 144.88 kg/mol
 NYesY (what is this?)  (verify)

Carlumab is a human monoclonal antibody designed for oncology and immune indications.[1][2]

Carlumab was developed by Johnson & Johnson.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association. 
  2. ^ World Health Organization (2010). "Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (4). Geneva: World Health Organization. p. 361. ISSN 1010-9609. Retrieved 17 August 2015.